All-cause mortality among patients with hidradenitis suppurativa: A population-based cohort study in the United States - 12/09/19
Abstract |
Background |
The mortality risk for patients with hidradenitis suppurativa (HS) is largely unknown.
Objective |
To compare mortality risk among individuals with and without HS in the United States.
Methods |
Retrospective cohort study in a population sample identified by using electronic health records data between January 1, 2012, and December 31, 2016. Primary outcome was incidence of 5-year all-cause mortality.
Results |
The crude 5-year mortality rate among patients with HS was 2.4% (321/13 289), compared with 2.7% (18 508/685 573) among control individuals. In the fully adjusted model, the increase in HS mortality risk was 14% (odds ratio [OR], 1.14; 95% confidence interval [CI], 1.01-1.28). Overall, excess risk of death attributable to HS was 3.1 deaths per 1000 patients (95% CI, 0.2-6.0) during the study period. Characteristics associated with mortality among patients with HS included age (OR, 1.05; 95% CI, 1.04-1.06), male sex (OR, 1.40; 95% CI, 1.09-1.79), ever-smoking status (OR, 1.48; 95% CI, 1.16-1.92), and Charlson Comorbidity Index score (OR, 1.25; 95% CI, 1.21-1.29).
Limitations |
The follow-up period may not have been long enough to assess the influence of disease severity or duration on mortality.
Conclusion |
HS appears to confer an independent risk of all-cause mortality. This risk is also influenced by tobacco smoking and comorbidities, which may be modifiable.
Le texte complet de cet article est disponible en PDF.Key words : comorbidities, comorbidity, hidradenitis suppurativa, mortality
Abbreviations used : BMI, CCI, HS, ICD, OR
Plan
| Funding sources: Supported in part by an education grant from AbbVie. The sponsor had no role in the design and conduct of the study; collection, management, analysis and interpretation of data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. |
|
| Disclosure: Dr Garg has served as an advisor for AbbVie, Pfizer, Janssen, Asana Biosciences, and UCB and has received honoraria. Ms Reddy and Dr Strunk have no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
Vol 81 - N° 4
P. 937-942 - octobre 2019 Retour au numéro
Article précédent
- Acute inflammatory edema: A mimicker of cellulitis in critically ill patients
- Elizabeth M. Marchionne, Timothy H. McCalmont, Laura B. Pincus, Philip E. LeBoit, Lindy P. Fox
- Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis
- Alexander Egeberg, Jacob P. Thyssen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?